Werewolf Therapeutics, Inc. Common Stock earnings per share and revenue
On 04 de nov. de 2025, HOWL reported earnings of -0.36 USD per share (EPS) for Q3 25, beating the estimate of -0.39 USD, resulting in a 9.50% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.63% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analistas forecast an EPS of -0.35 USD, with revenue projected to reach -- USD, implying an diminuir of -2.78% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
What were Werewolf Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Werewolf Therapeutics, Inc. Common Stock reported EPS of -$0.36, beating estimates by 9.5%, and revenue of $0.00, 0% as expectations.
How did the market react to Werewolf Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -7.63%, changed from $1.31 before the earnings release to $1.21 the day after.
When is Werewolf Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 02 de mar. de 2026.
What are the forecasts for Werewolf Therapeutics, Inc. Common Stock's next earnings report?
Based on 8
analistas, Werewolf Therapeutics, Inc. Common Stock is expected to report EPS of -$0.35 and revenue of -- for Q4 2025.